GNPX - Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
- U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes
- The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body
- The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced a new license agreement in relation to a gene therapy for both Type 1 and Type 2 diabetes
- The company’s novel infusion process using related gene therapy has shown statistically significant results in preclinical testing and Genprex anticipates a pending Phase I trial following the generation of sufficient preclinical data
Clinical-stage cancer and diabetes gene therapy developer Genprex (NASDAQ: GNPX) continues to expand its intellectual property portfolio for the company’s diabetes gene therapy program, recently announcing that it has entered into an exclusive license agreement related to a particular gene therapy for both Type 1 and Type 2 diabetes.
Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and...
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.